Aclarion, Inc. ACON 深 沪
等待开盘 09-18 09:30:00 美东时间
7.6265
-0.043
-0.57%
华盛通- 最 高7.74
- 今 开7.73
- 成交量 2101股
- 最 低 7.51
- 昨 收 7.67
- 总市值 444.17万
- 52周最高 3499.5105
- 市盈率 静 --
- 换手率 0.36%
- 52周最低 6.20
- 委 比 63.27%
- 总股本 58.24万
- 历史最高 586116.00
- 量 比 0.23
- 振 幅 3.00%
- 历史最低 7.51
- 每 手 1
- 风险率 715.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aclarion taps Greg Gould as CFO
Aclarion (NASDAQ:ACON) has appointed Greg Gould as chief financial officer, effective immediately. Greg brings more than 30 years of public and private company experience, serving as CFO of Nanos Heal...
09-03 18:23
Aclarion Appoints Greg Gould as Chief Financial Officer
Aclarion, Inc. announced the appointment of Greg Gould as Chief Financial Officer (CFO) to lead the company's financial strategy and growth. Gould, with over 30 years of experience in public and private companies, replaces long-time CFO John Lorbiecki, who is retiring. Gould has a strong track record in capital raising, driving profitability, and strategic transactions. Aclarion's CEO, Brent Ness, expressed confidence in Gould's ability to enhanc...
09-03 10:00
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.
08-16 03:35
Aclarion Q2 EPS $(2.75) Misses $(2.26) Estimate, Sales $19.319K Miss $30.000K Estimate
Aclarion (NASDAQ:ACON) reported quarterly losses of $(2.75) per share which missed the analyst consensus estimate of $(2.26) by 21.68 percent. This is a 99.8 percent increase over losses of $(1.36 thousand) per share
08-15 05:44
Auddia Plans Merger With AI-Focused Thramann Holdings, Will Rebrand as New Public Tech Powerhouse
Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) ("Auddia" or the "Company"), today announced that in follow up to the leadership and strategic changes announced last month the Company's Board, acting upon the recommendation of
08-05 18:10
Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts
Aclarion, Inc. announced a 132% year-over-year increase in Nociscan scan volumes from Q2 2024 to Q2 2025, driven by new physician adoption and insurance coverage in the UK. The company achieved two consecutive quarters of growth for the first time and expects continued quarterly growth. A cost-effectiveness analysis published in a peer-reviewed journal demonstrated Nociscan's superiority over provocative discography, supporting payer coverage. Th...
08-05 10:00
Aclarion, Inc. Adjourns Annual Meeting to Solicit Votes
Aclarion, Inc. ( ($ACON) ) has shared an announcement. On July 7, 2025, Aclario...
07-08 04:51
Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders
Aclarion, Inc. has announced that its Annual Meeting of Stockholders, originally scheduled for July 7, 2025, has been adjourned to July 21, 2025, at 9:30 a.m. Mountain Time, to allow additional time for stockholder voting. The meeting will continue to be held at the Company’s corporate office in Broomfield, Colorado. The record date for stockholder eligibility remains May 9, 2025. Proxies previously submitted will be voted unless revoked, and sto...
07-07 20:01
Jasper Reports 89% Response Rate in Urticaria Study, Halts Asthma Program After Drug Lot Issue
Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as
07-07 19:33
Pliant ends development of idiopathic pulmonary fibrosis asset bexotegrast
Pliant Therapeutics is ending development of idiopathic pulmonary fibrosis candidate bexotegrast following poor phase 2b/3 results. In March, the company ended the BEACON-IPF trial following a Data Sa...
06-28 04:32
